Semin Thromb Hemost
DOI: 10.1055/a-2528-5425
Review Article

Anti-platelet Factor 4 Antibody-Mediated Disorders: An Updated Narrative Review

Angela Napolitano
1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
,
1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
,
Marta Biolo
1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
,
Claudia Maria Radu
1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
,
Serena Toffanin
1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
,
Elena Campello
1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
,
Paolo Simioni
1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
› Author Affiliations

Abstract

Anti-platelet factor 4 (PF4) antibody-mediated disorders are a heterogeneous group of diseases characterized by the presence of highly pathogenic immunoglobulins G directed against PF4 and/or PF4/heparin complexes. These antibodies are able to activate platelets, neutrophils, and monocytes, thus resulting in thrombocytopenia and a hypercoagulable state. Five different forms of anti-PF4 antibody-mediated disorders have been identified: (1) classic heparin-induced thrombocytopenia (HIT) mediated by heparin and certain polyanionic drugs; (2) autoimmune HIT characterized by the presence of anti-PFA/polyanion antibodies that can strongly activate platelets even in the absence of heparin; (3) spontaneous HIT characterized by thrombocytopenia and thrombosis without proximate exposure to heparin, with two subtypes: (a) post-total knee arthroplasty and cardiac surgery using cardiopulmonary bypass or extracorporeal membrane oxygenation and (b) postinfections; (4) vaccine-induced immune thrombotic thrombocytopenia (VITT) characterized by thrombocytopenia, arterial and venous thrombosis, or secondary hemorrhage after receiving adenoviral vector vaccines for coronavirus disease 2019; (5) VITT-like disorders triggered by adenoviral infections. Although extremely rare and largely unknown, there has been growing interest in the VITT syndrome in recent years due to its clinical relevance. Timely detection of these antibodies is crucial for the diagnosis and treatment of anti-PF4 antibody-mediated disorders, via anti-PF4 antibody immunoassays using several antibody capture systems (e.g., enzyme-linked immunosorbent assay-based, particle gel, turbidimetry) and functional assays (e.g., serotonin release assay or heparin-induced platelet activation). We aimed to present the latest on laboratory findings, clinical characteristics, and therapeutic approaches for anti-PF4 antibody-mediated disorders.

Authors' Contributions

A.N. and L.S.: writing—original draft; M.B.: writing—“laboratory findings;” C.M.R. and S.T.: lab experiments—[Fig. 5]; E.C. and P.S.: writing—review and editing.




Publication History

Accepted Manuscript online:
30 January 2025

Article published online:
19 February 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Greinacher A, Schönborn L, Siegerist F. et al. Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT). Semin Hematol 2022; 59 (02) 97-107
  • 2 Greinacher A, Holtfreter B, Krauel K. et al. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood 2011; 118 (05) 1395-1401
  • 3 Hursting MJ, Pai PJ, McCracken JE. et al. Platelet factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol 2010; 134 (05) 774-780
  • 4 Morgan FJ, Begg GS, Chesterman CN. Complete covalent structure of human platelet factor 4. Thromb Haemost 1980; 42 (05) 1652-1660
  • 5 Krauel K, Pötschke C, Weber C. et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011; 117 (04) 1370-1378
  • 6 Warkentin TE. Platelet-activating anti-PF4 disorders: an overview. Semin Hematol 2022; 59 (02) 59-71
  • 7 Dehmer GJ, Fisher M, Tate DA, Teo S, Bonnem EM. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. Circulation 1995; 91 (08) 2188-2194
  • 8 Demma L, Levy JH. A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass. Anesth Analg 2012; 115 (06) 1273-1278
  • 9 Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review. Semin Thromb Hemost 2023; 49 (06) 621-633
  • 10 Dupuy A, Liu X, Tieng J. et al. Endothelial cell activation enhances thromboinflammation in VITT. Blood 2022; 140 (Suppl. 01) 1656-1657
  • 11 Rauova L, Poncz M, McKenzie SE. et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005; 105 (01) 131-138
  • 12 Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 2001; 138 (01) 22-31
  • 13 Warkentin TE, How I. How I diagnose and manage HIT. Hematology (Am Soc Hematol Educ Program) 2011; 2011: 143-149
  • 14 Marchetti M, Zermatten MG, Bertaggia Calderara D, Aliotta A, Alberio L. Heparin-induced thrombocytopenia: a review of new concepts in pathogenesis, diagnosis, and management. J Clin Med 2021; 10 (04) 683
  • 15 Arepally GM. Heparin-induced thrombocytopenia. Blood 2017; 129 (21) 2864-2872
  • 16 Liu Z, Li L, Zhang H. et al. Platelet factor 4(PF4) and its multiple roles in diseases. Blood Rev 2024; 64: 101155
  • 17 Greinacher A. Clinical Practice. Heparin-induced thrombocytopenia. N Engl J Med 2015; 373 (03) 252-261
  • 18 Warkentin TE. Laboratory diagnosis of heparin-induced thrombocytopenia. Int J Lab Hematol 2019; 41 (Suppl. 01) 15-25
  • 19 Cuker A, Arepally GM, Chong BH. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2018; 2 (22) 3360-3392
  • 20 Tardy B, Lecompte T, Mullier F, Vayne C, Pouplard C. Detection of platelet-activating antibodies associated with heparin-induced thrombocytopenia. J Clin Med 2020; 9 (04) 1226
  • 21 Warkentin TE, Davidson BL, Büller HR. et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest 2011; 140 (02) 366-373
  • 22 Favaloro EJ, Pasalic L, Henry B, Lippi G. Laboratory testing for platelet factor 4 antibodies: differential utility for diagnosis/exclusion of heparin induced thrombocytopenia versus suspected vaccine induced thrombotic thrombocytopenia. Pathology 2022; 54 (03) 254-261
  • 23 Husseinzadeh HD, Gimotty PA, Pishko AM, Buckley M, Warkentin TE, Cuker A. Diagnostic accuracy of IgG-specific versus polyspecific enzyme-linked immunoassays in heparin-induced thrombocytopenia: a systematic review and meta-analysis. J Thromb Haemost 2017; 15 (06) 1203-1212
  • 24 Sachs UJ, Cooper N, Czwalinna A. et al. PF4-dependent immunoassays in patients with vaccine-induced immune thrombotic thrombocytopenia: results of an interlaboratory comparison. Thromb Haemost 2021; 121 (12) 1622-1627
  • 25 Warkentin TE, Arnold DM, Sheppard JI, Moore JC, Kelton JG, Nazy I. Investigation of anti-PF4 versus anti-PF4/heparin reactivity using fluid-phase enzyme immunoassay for 4 anti-PF4 disorders: classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, vaccine-induced immune thrombotic thrombocytopenia, and spontaneous HIT. J Thromb Haemost 2023; 21 (08) 2268-2276
  • 26 Warkentin TE. Heparin-induced thrombocytopenia (and autoimmune heparin-induced thrombocytopenia): an illustrious review. Res Pract Thromb Haemost 2023; 7 (08) 102245
  • 27 Warkentin TE, Nazy I, Sheppard JI, Smith JW, Kelton JG, Arnold DM. Serotonin-release assay-negative heparin-induced thrombocytopenia. Am J Hematol 2020; 95 (01) 38-47
  • 28 Vayne C, Rollin J, Gruel Y. et al. PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia. N Engl J Med 2021; 385 (04) 376-378
  • 29 Greinacher A, Selleng K, Palankar R. et al. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood 2021; 138 (22) 2256-2268
  • 30 Lee CSM, Liang HPH, Connor DE. et al. A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia. Blood Adv 2022; 6 (11) 3494-3506
  • 31 Lee CSM, Powell MC, Chen VM. Whole blood procoagulant platelet flow cytometry protocol for heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombotic thrombocytopenia (VITT) testing. Methods Mol Biol 2023; 2663: 441-461
  • 32 Zlamal J, Aliotta A, Alberio L, Chen V, Bakchoul T, Platelet SSC. SSC Platelet Immunology of the ISTH. Diagnostic value of antibody-induced procoagulant platelets in heparin-induced thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost 2024; 22 (03) 860-868
  • 33 Tomer A, Masalunga C, Abshire TC. Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation. Am J Hematol 1999; 61 (01) 53-61
  • 34 Skornova I, Simurda T, Stanciakova L. et al. A functional assay for the determination of heparin-induced thrombocytopenia via flow cytometry. Diagnostics (Basel) 2023; 13 (18) 3019
  • 35 Tardy-Poncet B, Montmartin A, Piot M. et al; On Behalf Of The Gfht-Hit Study Group. Functional flow cytometric assay for reliable and convenient heparin-induced thrombocytopenia diagnosis in daily practice. Biomedicines 2021; 9 (04) 332
  • 36 Runser A, Schaning C, Allemand F, Amiral J. An optimized and standardized rapid flow cytometry functional method for heparin-induced thrombocytopenia. Biomedicines 2021; 9 (03) 296
  • 37 Padmanabhan A, Jones CG, Bougie DW. et al. A modified PF4-dependent, CD62p expression assay selectively detects serotonin-releasing antibodies in patients suspected of HIT. Thromb Haemost 2015; 114 (06) 1322-1323
  • 38 Kanack AJ, Singh B, George G. et al. Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. Am J Hematol 2022; 97 (05) 519-526
  • 39 Samuelson Bannow B, Warad DM, Jones CG. et al. A prospective, blinded study of a PF4-dependent assay for HIT diagnosis. Blood 2021; 137 (08) 1082-1089
  • 40 Handtke S, Wolff M, Zaninetti C. et al. A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination. Blood 2021; 137 (26) 3656-3659
  • 41 Huynh A, Kelton JG, Arnold DM, Daka M, Nazy I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature 2021; 596 (7873): 565-569
  • 42 Brown JA, Aranda-Michel E, Kilic A. et al. Outcomes with heparin-induced thrombocytopenia after cardiac surgery. Ann Thorac Surg 2021; 112 (02) 487-493
  • 43 Pishko AM, Cuker A. Heparin-induced thrombocytopenia and cardiovascular surgery. Hematology (Am Soc Hematol Educ Program) 2021; 2021 (01) 536-544
  • 44 Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003; 76 (06) 2121-2131
  • 45 Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Clin Med 2023; 12 (21) 6921
  • 46 Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost 2017; 15 (11) 2099-2114
  • 47 Manji F, Warkentin TE, Sheppard JI, Lee A. Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban. Platelets 2020; 31 (01) 124-127
  • 48 Doucette K, DeStefano CB, Jain NA, Cruz AL, Malkovska V, Fitzpatrick K. Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG). Res Pract Thromb Haemost 2017; 1 (01) 134-137
  • 49 Roberge G, Tritschler T, MacGillivray C, Dufresne L, Nagpal SK, Scarvelis D. Persisting autoimmune heparin-induced thrombocytopenia after elective abdominal aortic aneurysm repair: a case report. J Thromb Thrombolysis 2020; 50 (03) 674-677
  • 50 Arcinas LA, Manji RA, Hrymak C, Dao V, Sheppard JI, Warkentin TE. Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin. Transfusion 2019; 59 (06) 1924-1933
  • 51 Warkentin TE. Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. Expert Opin Drug Saf 2014; 13 (01) 25-43
  • 52 Dougherty JA, Yarsley RL. Intravenous immune globulin (IVIG) for treatment of autoimmune heparin-induced thrombocytopenia: a systematic review. Ann Pharmacother 2021; 55 (02) 198-215
  • 53 Makita N, Ohara T, Tsuji Y. et al. Early high-dose intravenous immunoglobulin for refractory heparin-induced thrombocytopenia with stroke: two case reports. J Stroke Cerebrovasc Dis 2023; 32 (04) 107032
  • 54 Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Rev Hematol 2019; 12 (08) 685-698
  • 55 Kudo Y, Suzuki K, Maezawa S, Seo R, Irinoda T. High-dose immunoglobulin therapy for multiple thromboembolism in persisting heparin-induced thrombocytopenia. Cureus 2024; 16 (03) e55747
  • 56 Batool A, Chaudhry S, Javaid A, Kenney A. Autoimmune heparin-induced thrombocytopenia: a diagnostic and management challenge after transcatheter aortic valve replacement. Cureus 2023; 15 (09) e45453
  • 57 Warkentin TE, Greinacher A. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia. Thromb Res 2021; 204: 40-51
  • 58 Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of 'spontaneous' HIT?. J Thromb Haemost 2008; 6 (09) 1598-1600
  • 59 Pruthi RK, Daniels PR, Nambudiri GS, Warkentin TE. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery 'spontaneous' HIT. J Thromb Haemost 2009; 7 (03) 499-501
  • 60 Mallik A, Carlson KB, DeSancho MT. A patient with 'spontaneous' heparin-induced thrombocytopenia and thrombosis after undergoing knee replacement. Blood Coagul Fibrinolysis 2011; 22 (01) 73-75
  • 61 Ketha S, Smithedajkul P, Vella A, Pruthi R, Wysokinski W, McBane R. Adrenal haemorrhage due to heparin-induced thrombocytopenia. Thromb Haemost 2013; 109 (04) 669-675
  • 62 Warkentin TE, Basciano PA, Knopman J, Bernstein RA. Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. Blood 2014; 123 (23) 3651-3654
  • 63 Warkentin TE, Safyan EL, Linkins LA. Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages. N Engl J Med 2015; 372 (05) 492-494
  • 64 Elshoury A, Khedr M, Abousayed MM, Mehdi S. Spontaneous heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages and pulmonary embolism after total knee arthroplasty. Arthroplast Today 2015; 1 (03) 69-71
  • 65 Baker K, Lim MY. Spontaneous heparin-induced thrombocytopenia and venous thromboembolism following total knee arthroplasty. Case Rep Hematol 2017; 2017: 4918623
  • 66 Ly BA, Quintero L. Adrenal insufficiency from unilateral adrenal hemorrhage in a patient on. Rivaroxaban thromboprophylaxis. AACE Clin Case Rep 2019; 5 (01) e70-e72
  • 67 Alidoost M, Soomro R, Gubeladze A. et al. Rivaroxaban related bilateral adrenal hemorrhage: a rare complications of direct oral anticoagulants - a case reports. Am J Case Rep 2019; 20: 1607-1611
  • 68 Mohanty E, Nazir S, Sheppard JI, Forman DA, Warkentin TE. High-dose intravenous immunoglobulin to treat spontaneous heparin-induced thrombocytopenia syndrome. J Thromb Haemost 2019; 17 (05) 841-844
  • 69 Swarup S, Kopel J, Yendala R, Thirumala S, Quick DP. Spontaneous heparin induced thrombocytopenia (HIT) following curettage and bone graft of femur in a patient with monostotic fibrous dysplasia. Thromb Res 2020; 196: 75-77
  • 70 Hwang SR, Wang Y, Weil EL, Padmanabhan A, Warkentin TE, Pruthi RK. Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty. Platelets 2021; 32 (07) 936-940
  • 71 Yoshida R, Tanaka A, Yoshioka N, Yokote J. Heparin 'flush' induced thrombocytopenia triggered by total hip replacement: a case report. Eur Heart J Case Rep 2020; 4 (02) 1-5
  • 72 Hornick J, Ayafor G. Spontaneous heparin induced thrombocytopenia: when a post-op pulmonary embolism isn't just a post-op pulmonary embolism. J Am Coll Cardiol 2020; 75: 3179
  • 73 Saengboon S, Chinthammitr Y, Kanitsap N. Spontaneous heparin-induced thrombocytopaenia with adrenal haemorrhage following orthopaedic surgery: a case report and literature review. BMJ Case Rep 2021; 14 (11) e245385
  • 74 Olevsky OM, Rosove MH. “Spontaneous” heparin-induced thrombocytopenia and thrombosis after total knee arthroplasty: a report of 2 cases. Arthroplast Today 2021; 9: 50-52
  • 75 Krauel K, Weber C, Brandt S. et al. Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. Blood 2012; 120 (16) 3345-3352
  • 76 Grigorian A, Schubl S, Barrios Jr C. et al. Association of heparin-induced thrombocytopenia with bacterial infection in trauma patients. JAMA Surg 2018; 153 (10) 964-965
  • 77 Rigamonti E, Bonora T, Ventresca M, Cippà P. Heparin-induced thrombocytopenia following Shiga-toxin-associated hemolytic uremic syndrome: a case report. J Med Case Rep 2022; 16 (01) 384
  • 78 Sugioka S, Doi Y, Ishihara T. et al. A case of heparin-induced thrombocytopenia (HIT) triggered by methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Ren Replace Ther 2016; 2: 62
  • 79 Olah Z, Kerenyi A, Kappelmayer J, Schlammadinger A, Razso K, Boda Z. Rapid-onset heparin-induced thrombocytopenia without previous heparin exposure. Platelets 2012; 23 (06) 495-498
  • 80 Becker CJ, Heston AL, Carrera JF. Spontaneous heparin-induced thrombocytopenia presenting as acute ischemic stroke. Neurol Clin Pract 2021; 11 (06) e918-e920
  • 81 Kwan C, Reimers J, o'Gorman C, Bird R, Brown H. Multiterritorial strokes in the setting of spontaneous heparin-induced thrombocytopaenia syndrome. BMJ Case Rep 2022; 15 (02) e244143
  • 82 Okata T, Miyata S, Miyashita F, Maeda T, Toyoda K. Spontaneous heparin-induced thrombocytopenia syndrome without any proximate heparin exposure, infection, or inflammatory condition: atypical clinical features with heparin-dependent platelet activating antibodies. Platelets 2015; 26 (06) 602-607
  • 83 Irani M, Siegal E, Jella A, Aster R, Padmanabhan A. Use of intravenous immunoglobulin G to treat spontaneous heparin-induced thrombocytopenia. Transfusion 2019; 59 (03) 931-934
  • 84 Newton F, Glaser K, Reeves J, Sheperd L, Ray B. Refractory heparin-induced thrombocytopenia in a patient with subarachnoid hemorrhage-a clinical conundrum. Neurohospitalist 2021; 11 (04) 360-364
  • 85 Perrin J, Barraud D, Toussaint-Hacquard M, Bollaert PE, Lecompte T. Rapid onset heparin-induced thrombocytopenia (HIT) without history of heparin exposure: a new case of so-called 'spontaneous' HIT. Thromb Haemost 2012; 107 (04) 795-797
  • 86 Ueland T, Hausberg I, Mørtberg TV. et al. Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology. Platelets 2022; 33 (04) 640-644
  • 87 Pascreau T, Ballester MC, Van Dreden P. et al. The high frequency of anti-PF4/heparin antibodies in patients with COVID-19 is neither related to heparin treatment or to an increased incidence of thrombosis. Clin Chem Lab Med 2021; 59 (11) e405-e408
  • 88 Piccin A, Mullin B, Brown A, Benson G. The lack of anti-PF4 antibodies in convalescent plasma from COVID-19 infected blood donor. Transfus Med 2023; 33 (03) 272-273
  • 89 Shiuan E, Sharma D, Ely EW, Moodabagil N, Tillman BF. Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection. J Thromb Thrombolysis 2022; 54 (02) 367-371
  • 90 Pai M. Epidemiology of VITT. Semin Hematol 2022; 59 (02) 72-75
  • 91 See I, Lale A, Marquez P. et al. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021. Ann Intern Med 2022; 175 (04) 513-522
  • 92 de Buhr N, Baumann T, Werlein C. et al. Insights into immunothrombotic mechanisms in acute stroke due to vaccine-induced immune thrombotic thrombocytopenia. Front Immunol 2022; 13: 879157
  • 93 Kanack AJ, Padmanabhan A. Vaccine-induced immune thrombotic thrombocytopenia. Best Pract Res Clin Haematol 2022; 35 (03) 101381
  • 94 Craven B, Lester W, Boyce S. et al. Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis. Blood 2022; 139 (16) 2553-2560
  • 95 Asif S, Kesireddy M, Koepsell SA, Gonzalez-Castellon MA, Gundabolu K, Baljevic M. Cerebral venous sinus thrombosis due to thrombosis with thrombocytopenia syndrome following Ad26.COV2.S: a first real-world case report of a male subject. Neurohospitalist 2022; 12 (02) 346-351
  • 96 Cines DB, Greinacher A. Vaccine-induced immune thrombotic thrombocytopenia. Blood 2023; 141 (14) 1659-1665
  • 97 Rzymski P, Perek B, Flisiak R. Thrombotic thrombocytopenia after COVID-19 vaccination: in search of the underlying mechanism. Vaccines (Basel) 2021; 9 (06) 559
  • 98 Chen QT, Liu Y, Chen YC. et al. Case report: vaccine-induced immune thrombotic thrombocytopenia complicated by acute cerebral venous thrombosis and hemorrhage after AstraZeneca vaccines followed by Moderna COVID-19 vaccine booster and surgery. Front Neurol 2022; 13: 989730
  • 99 Savulescu F, Cirlan C, Iordache-Petrescu MI, Iordache M, Petrescu AB, Blajut C. Portal vein and mesenteric artery thrombosis following the administration of an Ad26.COV2-S vaccine-first case from Romania: a case report. Vaccines (Basel) 2022; 10 (11) 1950
  • 100 Yelne P, Kabra R, Mathurkar S, Gaidhane SA, Acharya S, Kumar S. Relationship between vaccination and immune thrombotic thrombocytopenia: coincidental or causal?. Cureus 2022; 14 (08) e28560
  • 101 Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J Neurol Sci 2021; 428: 117607
  • 102 MacNeil JR, Su JR, Broder KR. et al. Updated recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients - United States, April 2021. MMWR Morb Mortal Wkly Rep 2021; 70 (17) 651-656
  • 103 Congiu T, Fanni D, Piras M. et al. Ultrastructural findings of lung injury due to vaccine-induced immune thrombotic thrombocytopenia (VITT) following COVID-19 vaccination: a scanning electron microscopic study. Eur Rev Med Pharmacol Sci 2022; 26 (01) 270-277
  • 104 Kashir J, Ambia AR, Shafqat A, Sajid MR, AlKattan K, Yaqinuddin A. Scientific premise for the involvement of neutrophil extracellular traps (NETs) in vaccine-induced thrombotic thrombocytopenia (VITT). J Leukoc Biol 2022; 111 (03) 725-734
  • 105 McGonagle D, De Marco G, Bridgewood C. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. J Autoimmun 2021; 121: 102662
  • 106 Dabbiru VAS, Müller L, Schönborn L, Greinacher A. Vaccine-induced immune thrombocytopenia and thrombosis (VITT)-insights from clinical cases, in vitro studies and murine models. J Clin Med 2023; 12 (19) 6126
  • 107 Schönborn L, Greinacher A. Longitudinal aspects of VITT. Semin Hematol 2022; 59 (02) 108-114
  • 108 Johansen S, Laegreid IJ, Ernstsen SL. et al. Thrombosis and thrombocytopenia after HPV vaccination. J Thromb Haemost 2022; 20 (03) 700-704
  • 109 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101
  • 110 Arepally GM, Ortel TL. Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. Blood 2021; 138 (04) 293-298
  • 111 Greinacher A, Langer F, Makris M. et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT) - update on diagnosis and management considering different resources: response to comment from Yamada et al. J Thromb Haemost 2022; 20 (02) 542-543
  • 112 Oldenburg J, Klamroth R, Langer F. et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie 2021; 41 (03) 184-189
  • 113 Nazy I, Sachs UJ, Arnold DM. et al. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC Subcommittee on platelet immunology. J Thromb Haemost 2021; 19 (06) 1585-1588
  • 114 Favaloro EJ, Pasalic L, Lippi G. Antibodies against platelet factor 4 and their associated pathologies: from HIT/HITT to spontaneous HIT-like syndrome, to COVID-19, to VITT/TTS. Antibodies (Basel) 2022; 11 (01) 7
  • 115 Scutelnic A, Brodard J, Kremer Hovinga JA, Arnold M, Heldner MR. Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia—a narrative review. Clin Transl Neurosci 2022; 6: 11
  • 116 Pavord S, Scully M, Hunt BJ. et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med 2021; 385 (18) 1680-1689
  • 117 Greinacher A, Langer F, Makris M. et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT): update on diagnosis and management considering different resources. J Thromb Haemost 2022; 20 (01) 149-156
  • 118 Rizk JG, Gupta A, Sardar P. et al. Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: a review. JAMA Cardiol 2021; 6 (12) 1451-1460
  • 119 Warkentin TE. Ischemic limb gangrene with pulses. N Engl J Med 2015; 373 (07) 642-655
  • 120 Baker AT, Boyd RJ, Sarkar D. et al. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Sci Adv 2021; 7 (49) eabl8213
  • 121 Schönborn L, Esteban O, Wesche J. et al. Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure. Blood 2023; 142 (26) 2305-2314
  • 122 Greinacher A. Me or not me? The danger of spontaneity. Blood 2014; 123 (23) 3536-3538
  • 123 Greinacher A, Langer F, Schönborn L. et al. Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy. Haematologica 2022; 107 (05) 1219-1221
  • 124 Warkentin TE, Baskin-Miller J, Raybould AL. et al. Adenovirus-associated thrombocytopenia, thrombosis, and VITT-like antibodies. N Engl J Med 2023; 389 (06) 574-577
  • 125 Campello E, Biolo M, Simioni P. More on adenovirus-associated thrombocytopenia, thrombosis, and VITT-like antibodies. N Engl J Med 2023; 389 (18) 1729
  • 126 Khan Z, Patel I, Gardner T. et al. Recurrent stent thrombosis following myocardial infarction associated with VITT-like antibodies. JACC Case Rep 2024; 29 (05) 102234
  • 127 von Hundelshausen P, Lorenz R, Siess W, Weber C. Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors. Thromb Haemost 2021; 121 (11) 1395-1399
  • 128 Lindhoff-Last E, Schönborn L, Zaninetti C, Warkentin TE, Greinacher A. Rescue therapy in chronic prothrombotic autoimmune anti-PF4 disorder. N Engl J Med 2023; 389 (14) 1339-1341
  • 129 Müller L, Dabbiru VAS, Schönborn L, Greinacher A. Therapeutic strategies in FcγIIA receptor-dependent thrombosis and thromboinflammation as seen in heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT). Expert Opin Pharmacother 2024; 25 (03) 281-294
  • 130 Favaloro EJ, Henry BM, Lippi G. The complicated relationships of heparin-induced thrombocytopenia and platelet factor 4 antibodies with COVID-19. Int J Lab Hematol 2021; 43 (04) 547-558
  • 131 Bennett A, Choi PY, Tan CW. Platelet factor 4 immune disease: medical emergencies that look like heparin-induced thrombocytopenia. Intern Med J 2024; 54 (12) 2072-2076
  • 132 Wang JJ, Schönborn L, Warkentin TE. et al. Antibody fingerprints linking adenoviral anti-PF4 disorders. N Engl J Med 2024; 390 (19) 1827-1829
  • 133 Nilius H, Hamzeh-Cognasse H, Hastings J. et al. Proteomic profiling for biomarker discovery in heparin-induced thrombocytopenia. Blood Adv 2024; 8 (11) 2825-2834